KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Common Equity (2016 - 2026)

Abbott Laboratories' Common Equity history spans 18 years, with the latest figure at $52.7 billion for Q1 2026.

  • On a quarterly basis, Common Equity rose 9170.74% to $52.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $52.7 billion, a 9170.74% increase, with the full-year FY2025 number at $52.1 billion, up 107.25% from a year prior.
  • Common Equity hit $52.7 billion in Q1 2026 for Abbott Laboratories, up from $52.1 billion in the prior quarter.
  • Over the last five years, Common Equity for ABT hit a ceiling of $52.7 billion in Q1 2026 and a floor of -$8.7 billion in Q2 2022.
  • Historically, Common Equity has averaged $20.0 billion across 5 years, with a median of $24.9 billion in 2024.
  • Biggest five-year swings in Common Equity: tumbled 8783.67% in 2022 and later surged 30897.47% in 2023.
  • Tracing ABT's Common Equity over 5 years: stood at $35.3 billion in 2022, then dropped by 29.46% to $24.9 billion in 2023, then increased by 1.14% to $25.2 billion in 2024, then surged by 107.25% to $52.1 billion in 2025, then increased by 1.1% to $52.7 billion in 2026.
  • Business Quant data shows Common Equity for ABT at $52.7 billion in Q1 2026, $52.1 billion in Q4 2025, and $51.0 billion in Q3 2025.